Vitamin D in systemic lupus erythematosus: Potential beyond bone health

International Journal of Clinical Rheumatology

Volumn 4, Issue 3, 2009, Pages 297-309

  Reynolds, John A ^a   Bruce, Ian N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Autoimmunity; Calcitriol; Cardiovascular disease; Musculoskeletal pain; SLE; Systemic lupus erythematosus; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE;

ATHEROGENESIS; BLOOD VESSEL REACTIVITY; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; FATIGUE; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; KIDNEY DISEASE; MORTALITY; MUSCULOSKELETAL PAIN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RICKETS; SINGLE DRUG DOSE; SUN EXPOSURE; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 70949086351     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.19     Document Type: Review

References (109)

1. Ippolito A, Petri M.: An update on mortality in systemic lupus erythematosus. Clin. Exp. Rheumatol. 26, S72-S79 (2008).
2. Cunninghame GDS, Graham RR, Manku H et al: Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat. Genet. 40, 83-89 (2008).
3. Harley JB, Alarcon-Riquelme ME, Criswell LA et al: Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204-210 (2008).
4. Castro J, Balada E, Ordi-Ros J, Vilardell-Tarrés M: The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun. Rev. 7, 354-351 (2008).
5. Manson JJ, Isenberg DA: The pathogenesis of systemic lupus erythematosus. Neth. J. Med. 61, 343-346 (2003).
6. Okamura WH, Midland MM, Hammond MW et al: Chemistry and conformation of vitamin D molecules. J. Steroid Biochem. Mol. Biol. 53, 603-616 (1995).
7. Revellia A, Massobrioa M, Tesarik J: Nongenomic effects of 1α,25-dihydroxyvitamin D3. Trend. Endocrinol. Metab. 9, 419-427 (1998).
8. DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 80(Suppl.), S1689-S1696 (2004).
9. Holick M: Vitamin D status: measurement, interpretation, and clinical application. Ann. Epidemiol. 19, 73-78 (2009).
10. Zerwekh JE: Blood biomarkers of vitamin D status. Am. J. Clin. Nutr. 87(Suppl.), S1087-S1091 (2008).
11. Adams JS, Clemens TL, Parrish JA, Holick MF: Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N. Engl. J. Med. 306, 722-725 (1982).
12. Harris SS, Dawson-Hughes B: Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am. J. Clin. Nutr. 67, 1232-1236 (1998).
13. Millen AE, Bodnar LM: Vitamin D assessment in population-based studies: a review of the evidence. Am. J. Clin. Nutr. 87(Suppl.), S1102-S1105 (2008).
14. Binkley N: Vitamin D: clinical measurement and use. J. Musculoskelet. Neuronal Interact. 6(4), 338-340 (2006).
15. Hendy GN, Hruska KA, Mathew S, Goltzman D: New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int. 69, 218-223 (2006).
16. Khanal RC, Nemere I: Regulation of intestinal calcium transport. Annu. Rev. Nutr. 28, 179-196 (2008).
17. Kawahara M, Iwasaki Y, Sakaguchi K et al.: Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci. 82, 677-686 (2008).
18. Holick MF: Vitamin D deficiency. N. Engl. J. Med. 357, 266-281 (2007).
19. Lamprecht SA, Lipkin M: Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann. NY Acad. Sci. 952, 73-87 (2001).
20. Lehmann B: Role of the vitamin D3 pathway in healthy and diseased skin -facts, contradictions and hypotheses. Exp. Dermatol. 18, 97-108 (2009).
21. Mathieu C, Gysemans C, Giulietti A, Bouillon R: Vitamin D and diabetes. Diabetologia 48, 1247-1257 (2005).
22. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D: Role of vitamin D in the pathogenesis of Type 2 diabetes mellitus. Diabetes Obes. Metab. 10, 185-197 (2008).
23. Müller K, Kriegbaum NJ, Baslund B, Sørensen OH, Thymann M, Bentzen K: Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 4, 397-400 (1995).
24. Huisman AM, Whit KP, Algra A et al.: Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J. Rheumatol. 28, 2535-2539 (2001).
25. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C: Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 47, 920-923 (2008).
26. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS: Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 5, 114-117 (2006).
27. Borba VZC, Vieira JGH, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M: Vitamin D deficiency in patients with active systemic lupus erythematosus. Oesteoporos. Int. 20(3), 427-433 (2009).
28. Schoenmakers I, Goldberg GR, Prentice A: Abundant sunshine and vitamin D deficiency. Br. J. Nutr. 99, 1171-1173 (2008).
29. Millard TP, Hawk JLM, Mcgregor JM: Photosensitivity in lupus. Lupus 9, 3-10 (2000).
30. Cusack C, Danby C, Fallon JC et al.: Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol. Photoimmunol. Photomed. 24, 260-267 (2008).
31. Nesby-O'Dell S, Scanlon KS, Cogswell ME et al.: Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr. 76, 187-192 (2002).
32. Johnson AE, Gordon C, Palmer RG, Bacon PA: The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum. 38, 551-558 (1995).
33. Patel M, Clarke AM, Bruce IN, Symmons DP: The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum. 59, 2963-2969 (2006).
34. Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y: Anti-vitamin D, vitamin D in SLE: preliminary results. Ann. NY Acad. Sci. 1109, 550-557 (2007).
35. Szodoray P, Nakken B, Gaal J et al.: The complex role of vitamin D in autoimmune diseases. Scand. J. Immunol. 68, 261-269 (2008).
36. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM: Intake of vitamin D and risk of Type 1 diabetes: a birth-cohort study. Lancet 385, 1500-1503 (2001).
37. Nagy G, Koncz A, Perl A: T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 25, 123-140 (2005).
38. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J: Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 17, 371-375 (2008).
39. Gaipl US, Kuhn A, Sheriff A et al.: Clearance of apoptotic cells in human SLE. Curr. Dir. Autoimmun. 9, 173-187 (2006).
40. Llorente L, Richaud-Patin Y, Fior R et al.: In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum. 37, 1647-1655 (1994).
41. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J. Immunol. 147, 117-123 (1991).
42. La Cava A: T-regulatory cells in systemic lupus erythematosus. Lupus 17, 421-424 (2008).
43. Cross JT, Benton HP: The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm. Res. 8, 255-261 (1999).
44. 3 analogues as immunomodulatory agents. Trends Mol. Med. 8, 174-179 (2002).
45. Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, Mathieu C: Immune regulation of 25-hydroxyvitamin-D3-1-hydroxylase in human monocytes. J. Bone Miner. Res. 21, 37-47 (2006).
46. Giulietti A, van Etten E, Overbergha L, Stoffelsa K, Bouillona R, Mathieu C: Monocytes from Type 2 diabetic patients have a pro-inflammatory profile: 1,25-dihydroxyvitamin D3 works as anti-inflammatory. Diabetes Res. Clin. Pract. 77, 47-57 (2007).
47. Xu H, Soruri A, Gieseler RK, Peters JH: 1,25-dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity and phagocytosis of human monocytes. Scand. J. Immunol. 38, 535-540 (1993).
48. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164, 2405-2411 (2000).
49. 3. Involvement of NK-κB downregulation in transcriptional repression of the P40 gene. J. Clin. Invest. 101, 252-262 (1998).
50. Berkun Y, Verbovetski I, Ben-Ami A et al.: Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus. Eur. J. Immunol. 38, 2896-2904 (2008).
51. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE: Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179, 1634-1647 (2007).
52. Penna G, Amuchastegui S, Laverny G, Adorini L: Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells. J. Bone Miner. Res. 22, V69-V73 (2007).
53. Mahon BD, Wittke A, Weaver V et al.: The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J. Cell. Biochem. 89, 922-932 (2003).
54. Akahoshi M, Nakashima H, Tanaka Y et al.: Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 42, 1644-1648 (1999).
55. Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP: Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin. Immunol. 99, 82-93 (2001).
56. Waldman M, Madaio MP: Pathogenic autoantibodies in lupus nephritis. Lupus 14, 19-24 (2005).
57. 3 attenuates of expression of experimental murine lupus of MRL/1 mice. Autoimmunity. 12, 143-148 (1992).
58. 3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J. Clin. Lab. Anal. 14, 91-96 (2000).
59. Kozora E, Ellison MC, West S: Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE Neuropsychological Battery. Arthritis Rheum. 55, 628-635 (2006).
60. Krupp LB, LaRocca NG, Muir J, Steinberg AD: A study of fatigue in systemic lupus erythematosus. J. Rheumatol. 17, 1450-1452 (1990).
61. Wysenbeek AJ, Leibovici L, Weinberger A, Guedj D: Fatigue in systemic lupus erythematosus: prevalence and relation to disease expression. Br. J. Rheumatol. 32, 633-635 (1993).
62. Schott G, Wills M: Muscle weakness in osteomalacia. Lancet 2, 6262-6269 (1976).
63. Dhesi JK, Bearne LM, Moniz C et al.: Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J. Bone Miner. Res. 17, 891-897 (2002).
64. Pfeifer M, Begerow B, Minne HW et al.: Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp. Clin. Endocrinol. Diabetes 109, 87-92 (2001).
65. Visser M, Deeg DJ, Lips P: Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J. Clin. Endocrinol. Metab. 88, 5766-5772 (2003).
66. Inderjeeth CA, Glennon D, Petta A, Soderstrom J, Boyatzis I, Tapper J: Vitamin D and muscle strength in patients with previous fractures. NZ Med. J. 120(1262), U2730 (2007).
67. Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W: Vitamin D receptor expression in human muscle tissue decreases with age. J. Bone Miner. Res. 19, 265-269 (2004).
68. Thudi A, Yin S, Wandstrat AE, Li Q-Z, Olsen NJ: Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am. J. Med. Sci. 335, 99-104 (2000).
69. Hoogendijk WJ, Lips P, Dik MG, Deeg DJ, Beekman AT, Penninx BW: Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch. Gen. Psychiatry 65, 508-512 (2008).
70. Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K: Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J. Intern. Med. 26, 599-609 (2008).
71. Esdaile JM, Abrahamowicz M, Grodzicky T et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331-2337 (2001).
72. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G: Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 48, 3159-3167 (2003).
73. Manzi S, Meilahn EN, Rairie JE et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408-415 (1997).
74. Wyman RA, Mays ME, McBride PE, Stein JH: Ultrasound-detected carotid plaque as a predictor of cardiovascular events. Vasc. Med. 11, 123-130 (2006).
75. Roman MJ, Shanker BA, Davis A et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003).
76. Thompson T, Sutton-Tyrrell K, Wildman RP et al.: Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum. 58, 835-842 (2008).
77. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH: Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 29, 292-297 (2002).
78. El-Magadmi M, Bodill H, Ahmad Y et al.: Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110, 399-404 (2004).
79. Kiss E, Soltesz P, Der H et al.: Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J. Autoimmun. 27, 211-217 (2006).
80. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ESG, Tak PP: Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 47, 4-7 (2008).
81. McMahon M, Hahn BH: Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr. Opin. Immunol. 19, 633-639 (2007).
82. Anderson TW, Le Riche WH: Cold weather and myocardial infarction. Lancet 295, 291-296 (1970).
83. Dunnigan MG, Hariand WA, Fyfe T: Seasonal incidence and mortality of ischaemic heart disease. Lancet 296, 793-797 (1970).
84. Müller-Nordhorn J, Binting S, Roll S, Willich SN: An update on regional variation in cardiovascular mortality within Europe. Eur. Heart J. 29, 1316-1326 (2008).
85. Wang TJ, Pencina MJ, Booth SL et al.: Vitamin D deficiency and risk of cardiovascular disease. Circulation 116, 503-511 (2008).
86. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 186, 1174-1180 (2008).
87. Dobnig H, Pilz S, Scharnagl H et al.: Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340-1349 (2008).
88. Lund B, Badskjaer J, Lund Bj, Socrcnsen OH: Vitamin D and ischaemic heart disease. Horm. Metab. Res. 10, 553-556 (1978).
89. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int. J. Epidemiol. 19, 559-563 (1990).
90. Vik T, Try K, Thellc DS, Forde OH: Tromso Heart Study: vitamin D metabolism and myocardial infarction. Br. Med. J. 2, 176 (1979).
91. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC: Vitamin D intake and risk of incident hypertension results from three large prospective cohort studies. Hypertension 6, 676-682 (2005).
92. Judd SE, Nanes MS, Ziegler TR, Wilson PWF, Tangpricha V: Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the Third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr. 87, 136-141 (2008).
93. Margolis KL, Ray RM, van Horn L et al.: Effect of calcium and vitamin D supplementation on blood pressure: the women's health initiative randomized trial. Hypertension 52, 847-844 (2008).
94. Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 69, 842-856 (1999).
95. + channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol. Br. J. Pharmacol. 127, 772-778 (1999).
96. + channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol. Br. J. Pharmacol. 127, 772-778 (1999).
97. Laia PFH, Mohameda F, Mongea J-C, Stewart DJ: Downregulation of eNOS mRNA expression by TNF-α: identification and functional characterization of RNA-protein interactions in the 3'UTR. Cardiovasc. Res. 59, 160-168 (2003).
98. Yan G, You B, Chen S-P, Liao JK, Sun J: Tumor necrosis factor-α downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-α1. Circ. Res. 103, 591-597 (2008).
99. Talmor Y, Golan E, Benchetrit S et al.: Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am. J. Physiol. Renal. Physiol. 294, F1059-F1064 (2008).
100. Sugden JA, Davies I, Witham MD, Morris AD, Struthers AD: Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 25, 320-325 (2008).
101. Hansson GK, Robertson AKL, Soderberg-Naucler C: Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis. 1, 297-329 (2006).
102. 3 concentrations and carotid artery intima-media thickness among Type 2 diabetic patients. Clin. Endocrinol. 65, 593-597 (2006).
103. Bland R, Walker EA, Hughes SV, Stewart PM, Hewison M: Constitutive expression of 25 hydroxyvitamin D3-1a-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology 140, 2027-2034 (1999).
104. Zehnder D, Bland R, Chana RS et al.: Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 13, 621-629 (2002).
105. Somjen D, Weisman Y, Kohen F et al.: 25-hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111, 1666-1671 (2005).
106. 3 receptors and actions in vascular smooth muscle cells in vitro. Calcif. Tissue Int. 41, 112-114 (1987).
107. 3 in vitro coincides with impaired formation of elastic fibres. Int. J. Exp. Pathol. 89, 117-124 (2008).
108. Belmont HM, Buyon J, Giorno R, Abramson S: Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum. 37, 376-383 (1994).
109. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-κ B and cytokine-inducible enhancers. FASEB J. 9, 899-909 (1995).